Multiple Sclerosis Clinical Trials in San Antonio

Showing 201-220 of 435 trials

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

NCT03636256

This is a clinical trial studying the administration of NanoDoce as a direct injection to the bladder wall immediately after tumor resection and as an intravesical instillation. All participants will receive NanoDoce, and will be evaluated for safety and tolerability, as well as the potential effects of NanoDoce on urothelial carcinoma.

Bladder CancerUrothelial CarcinomaUrinary Bladder Neoplasm+6 more

NanOlogy, LLC36 participantsStarted Apr 2019

Phoenix, Arizona, United States • Baltimore, Maryland, United States • New York, New York, United States +2 more locations

COMPLETEDPhase 1/2< 1 mile

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

NCT03602079

Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity.

HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more

Klus Pharma Inc.49 participantsStarted Jul 2018

Sarasota, Florida, United States • Boston, Massachusetts, United States • Detroit, Michigan, United States +7 more locations

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Multiple Sclerosis Trials in Other Cities

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

An Extension of the TG1101-RMS201 Trial

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

A Safety Study of SGN-LIV1A in Breast Cancer Patients

A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression

A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms

Study of Diroximel Fumarate in the Real-World Setting

Dimethyl Fumarate (DMF) Observational Study

Safety Study of SEA-CD40 in Cancer Patients

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects

Relative Bioavailability of LY03010 Compared to Listed Drug

Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity

Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Other Conditions in San Antonio